ASXL3-targeted antisense oligonucleotide (personalized therapy)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for ASXL3-targeted antisense oligonucleotide (personalized therapy), covering 2025-09-29 to 2025-09-29. Get the full timeline:
Most recent: Clinical Trial Update: Personalized Antisense Oligonucleotide Therapy for A Single Participant With ASXL3 Gene Mutation [Phase 1, Phase 2]